Medtronic plc (MDT) SEC Filings & Earnings Calls

Tariff and trade policy uncertainty

“Recent developments in global trade policy have introduced new uncertainties for our business. The U.S., China, and other jurisdictions have recently imposed or proposed additional tariffs on imported goods.” · word for word

Italian payback liability uncertainty

“Discussions are ongoing between the Italian government and industry groups related to the applicability of this legislation for years 2019 and beyond, as such, it is possible that the amount of the Company’s liability could materially differ from the amount currently accrued.” · word for word

Mallinckrodt bankruptcy litigation

“The case will now proceed to discovery into the merits of the Trust’s intentional fraudulent transfer and related claims.” · word for word

Extra fiscal week in Q1 benefited organic growth by ~$570M; underlying growth may be lower.

“Company estimates the impact of the extra week benefited Q1 organic growth by approximately $570 million.” · word for word

Currency fluctuations could impact future results.

“Guidance includes estimated neutral to 1% accretive impact from FX.”

Integration risks from recent acquisitions (Scientia Vascular, SPR Therapeutics).

“Completed acquisitions of Scientia Vascular and SPR Therapeutics, Inc.” · word for word

Non-GAAP Operating Margin Compression

“Non-GAAP operating profit increased 2.4% and operating margin decreased 130 basis points year-over-year.” · word for word

Tariff and Geopolitical Exposure

“Results were within the Company’s initial annual guidance despite a range of external factors, including tariffs, geopolitical dynamics, market volatility, and the MiniMed initial public offering.” · word for word

Stock Option Underwater

“the stock option grant was under water as of the end of the fiscal year, with a $91.97 grant price compared to $83.32 fiscal year end price” · word for word

EPS Goal Miss in MIP

“While the EPS goal was not achieved, strong performance in revenue growth and free cash flow resulted in MIP payouts at 103% of target for FY26” · word for word

Tariff cost pressure

“Based on current rates as of June 3, 2026, we estimate the pre-tax net tariff impact to be $250 million in fiscal year 2027” · word for word

China revenue concentration

“China, which comprises approximately six percent of our total revenue” · word for word

Diabetes business separation risk

“The ongoing separation of our Diabetes Business could be delayed, may not be completed as currently contemplated, and could materially adversely affect our business” · word for word

Margin pressure from MiniMed Blackstone payment and tariffs.

“Q4 non-GAAP operating margin includes 160bps from MiniMed Blackstone payment and 80bps from tariffs.”

Leadership transition in key neuroscience portfolio; no disruption expected but transition risk exists.

“Departure with transition period through September 1, 2026.”

Cybersecurity incident could lead to data breach, regulatory fines, and reputational damage

“unauthorized third party had accessed data in certain of the Company’s information technology (“IT”) systems” · word for word

Potential personal information exposure requiring notifications and support services

“We are working to identify any personal information that may have been accessed and will provide notifications and support services as needed” · word for word

IPO dilution and royalty charge pressure near-term EPS

“MiniMed IPO dilution of $0.04/share and $157M charge for Blackstone royalty payments.”

Tariff cost pressure

“Based on current rates as of February 17, 2026, we estimate the pre-tax net tariff impact to be $185 million in fiscal year 2026, with the majority recognized in the consolidated statements of income in the second half of the fiscal year.” · word for word

Restructuring execution risk

“Restructuring charges, net for the three months ended January 23, 2026 were $77 million compared to $43 million for the prior year period.”

Diabetes separation uncertainty

“In May 2025, the Company announced its intent to separate the Diabetes business, with the intention to create a new independent, publicly traded company, MiniMed Group, Inc. (MiniMed). The separation is expected to be completed within 18 months of the initial announcement.” · word for word

Tariff exposure of ~$185M unchanged, could pressure EPS if not mitigated.

“This includes a potential impact from tariffs of approximately $185 million, unchanged from the prior guidance.” · word for word

Geopolitical conflicts and trade policy changes could disrupt supply chain or market access.

“Forward-looking statements... risks related to... geopolitical conflicts, changing global trade policies”

Tariff cost headwind

“Based on current rates as of November 18, 2025, we estimate the pre-tax net tariff impact to be $185 million in fiscal year 2026, with the majority recognized in the consolidated statements of income in the second half of the fiscal year.” · word for word

Diabetes separation execution risk

“In May 2025, the Company announced its intent to separate the Diabetes Operating Unit into a new standalone company, and its expectation to complete the separation within 18 months from the announcement date.” · word for word

Tariff impact of ~$185 million on FY26 EPS, unchanged from prior guidance.

“potential impact from tariffs of approximately $185 million, unchanged from the prior guidance” · word for word

Loss of key operations executive; potential disruption in enterprise operations.

“EVP Enterprise Operations Gregory L. Smith retiring effective December 2, 2025 to join a private equity-held organization.”